UnitedHealth stock rises into the weekend — what UNH investors watch before Jan. 27 results
UnitedHealth Group shares ended Friday up 1.9% at $336.40, closing out the first session of the year with a firm tone in managed care.
UnitedHealth stock ticks up after Barclays target hike as UNH earnings near
UnitedHealth Group Inc shares were up 0.8% at $338.94 in late-morning trading on Monday after Barclays raised its price target on the health insurer. The stock has traded between $333.86 and $340.29 so far, with about 2.4 million shares changing hands.
UnitedHealth stock today: UNH rises after hours as traders look ahead to January guidance
UnitedHealth Group shares were up about 1% at $332.16 in after-hours trading on Tuesday, following the 4 p.m. close. The stock ranged from $329.18 to $336.03 during the day’s session, with about 4.4 million shares traded.
UnitedHealth Group (UNH) Stock After Hours Today (Dec. 15, 2025): Key News, Analyst Forecasts, and What to Watch Before Tuesday’s Open
UnitedHealth Group Incorporated finished Monday’s regular session modestly lower and then drifted a touch further in after-hours trading—setting up a “watch-the-macro” Tuesday morning for managed-care investors.
Humana Stock (HUM) Outlook December 4, 2025: Earnings Beat, Legal Risks and 2026 Medicare Advantage Forecast
Humana’s share price spent most of 2025 behaving like a stressed-out cardiogram: sharp drops around guidance cuts and star-rating headlines, then sharp rebounds when the numbers looked less bad than feared.
PSTV Stock on November 25, 2025: FDA Meeting, Nasdaq Extension and Humana Deal Put Plus Therapeutics Back in Focus
As traders log in on Tuesday, November 25, 2025, Plus Therapeutics is back on the radar thanks to a cluster of late‑November catalysts: an FDA Type B meeting for lead radiotherapeutic REYOBIQ™, a fresh 180‑day Nasdaq bid‑price extension, and a national coverage agreement with Humana for its CNSide® cancer diagnostic.
Humana (HUM) Stock on Nov 5, 2025: Earnings Beat, Outlook Trimmed – Full Analysis
In summary, Humana Inc. faces a pivotal moment: it’s balancing short-term earnings headwinds from elevated costs and rating setbacks against strong long-term fundamentals in the Medicare Advantage space. The latest news provides some relief that management’s corrective actions are workingreuters.comreuters.com. However, caution prevails as 2026 looms without guidance and with likely flat profitsreuters.com. Investors should watch upcoming quarters for signs of cost trend stabilization, membership retention during open enrollment, and progress on quality metrics. Humana’s ability to navigate these challenges under new leadership will determine if the stock can regain its former strength. For now, the consensus is that Humana will weather the storm: it remains a market leader in a growing sector, with a strategy to adapt and thrive. As one analyst succinctly put it, “Humana’s crown slipped, but it’s far from lost.” The coming year will show how quickly that crown can be polished again.
Humana Hit Hard: Judge Upholds Medicare Advantage Star Cut, Stock Slides
Humana sued CMS in July after its star rating unexpectedly plunged. The insurer argued that CMS unfairly flagged three interpreter calls as failures, causing a 4.5-to-3.5 star drop reuters.com healthcaredive.com. On Oct. 14, U.S. District Judge Reed O’Connor rejected Humana’s arguments reuters.com. He found that CMS had acted “in accordance with its guidelines” and did not act arbitrarily fiercehealthcare.com. In particular, the judge upheld CMS’s no-callbacks policy for those language-line test calls as lawful healthcaredive.com.
Record Highs, AI Hype, and a Shutdown: Key Takeaways from U.S. Stock Markets (Oct 3–4, 2025)
Wall Street’s major indexes extended their rally into the first days of October, defying the political gridlock in Washington. On Friday, October 3, the benchmark S&P 500 edged up less than 0.1% to 6,715.79, just enough to mark a record closing high reuters.com. The Dow Jones Industrial Average climbed 0.5% to 46,758.28, also a record finish reuters.com. Meanwhile, the Nasdaq Composite slipped about –0.3% to 22,780.5, snapping its winning streak as some tech shares weakened reuters.com. Notably, all three indexes had hit intraday all-time highs during Friday’s session before a bit of profit-taking into the close reuters.com.
Humana Stock Skyrockets as Medicare Advantage News Ignites Rally
On Oct. 3, 2025 Humana’s stock surged sharply – closing up ~10.6% after a late afternoon rally stockstory.org. Intraday gains peaked around +11.9% as news broke that Humana’s Medicare Advantage star ratings and plan enhancements were better than feared. The Oct. 3 close near $283.72 was well above the ~$256 level of just days earlier, reflecting strong investor enthusiasm. Trading volume was heavy, and market commentary noted that moves of this size are rare even for Humana stockstory.org stockstotrade.com.
Humana (HUM) Stock Skyrockets on Medicare News – What Investors Must Know Today
As of midday Oct 3, Humana shares were $272.05, up about +6.01% on the day reuters.com. Yesterday’s close was $256.62 reuters.com, so HUM has recovered much of last week’s slide. In fact, Oct 1 saw a ~5% drop finviz.com, but Oct 2’s star rating news spurred a ~3% gain reuters.com. By Friday morning, industry data show HUM stock as one of the S&P 500’s top gainers reuters.com. Year‑to‑date Humana is roughly flat, trading ~19% below its 52-week high finviz.com.
TechStock² Updates
![UK Stock Market Today 29/08/2026 [UPDATE: 08:49 BST] [Weekly Recap + Week Ahead: Midcaps Lead Before Bailey and Gilt Auction]](https://ts2.tech/wp-content/uploads/2026/08/UK-market-dashboard-2026-08-29-0843-480x384.jpg "UK Stock Market Today 29/08/2026 [UPDATE: 08:49 BST] [Weekly Recap + Week Ahead: Midcaps Lead Before Bailey and Gilt Auction]")
